Treating late stage myeloma has multiple challenges. First of all, patients are usually more refractory to the most commonly used agents. And we know from old cohorts that if we see patients ...

Researchers sought to identify prognostic factors for survival in patients with newly diagnosed multiple myeloma.

1 Multiple myeloma ... all stages of disease, to hopefully drive deeper remissions and even cures. Above all, we are working to develop new ways to reduce the treatment burden so patients can ...

In a retrospective study of 315 patients with relapsed/refractory multiple myeloma, retreatment with ... International Staging System stage, revised International Staging System stage, and ...

During a Case-Based Roundtable® event, Muhammad Umair Mushtaq, MD, discussed managing long-term toxicity concerns related to ...

Genmab (GMAB) and Sonic Automotive (SAH) are climbing 5% and 3%, respectively, after investment banks issued favorable notes ...

The FDA has approved Sarclisa (isatuximab) as a first-line therapy for blood cancer multiple myeloma as a combination ... a subcutaneous formulation in late-stage development with clinical results ...

Linvoseltamab is an investigational B-cell maturation antigen CD3-targeted bispecific antibody. The BLA resubmission was needed as the original application could not be approved due to manufacturing ...

The PDUFA action date for an FDA decision for linvoseltamab to treat adult patients with relapsed/refractory multiple myeloma ...

Researchers sought to determine whether teclistamab would lead to a clinical response in patients with relapsed/refractory multiple myeloma.